"We expect Olin's first quarter 2025 adjusted EBITDA to be in the range of $150 million to $170 million, and we will continue Olin's disciplined capital allocation strategy to prioritize share ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... our research has shown that we can ...

On Wednesday, Bernstein analysts maintained their positive stance on Eli Lilly stock (NYSE:LLY), reiterating an Outperform ... which indicated a shortfall in the fourth quarter GLP-1 revenue compared ...